6
Press Release MAHLE Covid-19 worldwide vaccination initiatives
more
Stories about Medikament
Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic deramatitis in two Phase 3 trials
Barcelona (ots/PRNewswire) - - Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials - Safety profile consistent with prior lebrikizumab studies in atopic dermatitis Lebrikizumab led to significant improvements with ...
moreePresentation of the results of the in-vitro study regarding the anti-proliferative and pro-apoptotic effects of Polyphenon® E (Veregen®) at the 31st German Skin Cancer Congress on 10 September 2021
Strausberg (ots) - Aresus Pharma GmbH, a company of DERMAGO Holding GmbH, announced today that the abstract "Inhibition of cell-proliferation and cell viability by Polyphenon E ® (Veregen®) in cutaneous SCC cell lines" has been accepted as an e-poster short presentation at the 31st German Skin Cancer Congress. In ...
moreTechnische Universität München
The virus trap: hollow nano-objects made of DNA could trap viruses and render them harmless
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36810/ High resolution images: https://mediatum.ub.tum.de/1616943 NEWS RELEASE The virus trap Hollow ...
moreZOE Study Reveals Eating a Plant Rich Diet Reduces Risk of Developing COVID-19 and Going to the Hospital
more
2Tianjin Haihe Media Group presents the story of Zhang Boli in fighting COVID-19 with TCM
more
Tianjin Haihe Media Group presents the story of Zhang Boli in fighting COVID-19 with TCM
more- 3
Vascudyne Announces Successful First Human Use of TRUE Vascular Graft for Hemodialysis Access
more Technische Universität München
Versatile, fast and reliable: new automated microarray rapid test detects SARS-CoV-2 antibodies
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36762/ High resolution images: https://mediatum.ub.tum.de/1615381 NEWS RELEASE Versatile, fast and reliable SARS-CoV-2 antibody assay Automated microarray ...
moreTechnische Universität München
Animal health through genomics | Feasibility study: Preventing diseases through genome analysis and genome scissors
Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36757/ High resolution images: https://mediatum.ub.tum.de/1615373 Animal health through genomics Feasibility study: Preventing diseases ...
moreTechnische Universität München
In many cases, MS starts long before the diagnosis
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36707/ Picture: https://mediatum.ub.tum.de/1615270 NEWS RELEASE In many cases, MS starts long before the diagnosis Multiple sclerosis is often diagnosed years after the first symptoms appear Years before they ...
moreAM plays to its strengths in the medical field
One documentmore
European Inventor Award 2021: Meet some of today’s most inspiring innovators at digital event on 17 June
moreInvestment breakthrough for BrainRepair UG start-up – Stem cell treatment for newborns / Dr. Metin Colpan, founder of Nasdaq listed Qiagen N.V. acquired 5% of BrainRepair UG shares worth EUR 15M
moreTechnische Universität München
New AI technology protects privacy in medical diagnostics
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36689/ Highresolution pictures: https://mediatum.ub.tum.de/1612604 NEWS RELEASE New AI technology protects privacy Medical diagnostics algorithm identifies pneumonia in paediatric x-ray images AI algorithms can ...
moreDid my vaccine work? New rapid test for the determination of vaccination success
more- 2
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
more Prof. Dr. Heino Stöver - Sozialwissenschaftliche Suchtforschung
Expert for addiction studies, Prof. Dr. Heino Stöver, criticizes the new EU Beating Cancer Plan: "Target of less than 5 percent of smokers in the EU not achievable without harm reduction approach".
Frankfurt/Main (ots) - Prof. Dr. Heino Stöver has sharply criticized the EU Commission's "Beating Cancer Plan" presented today: "For years, the always same methods have been used trying to attain the ambitious goals of an almost tobacco-free continent. Tax increases, advertising bans and no-smoking zones are too ...
more
NOMOS Glashütte/SA Roland Schwertner KG
2Question time for one of the Doctors Without Borders
moreIEVA (Independent European Vape Alliance)
E-Cigarettes flavours ban in the Netherlands endangers Public Health
Brussels (ots) - Around 65 percent of adult vapers in Europe use fruit or sweet liquids. [1] The variety of flavours is one of the most important reasons for smokers to switch to e-cigarettes and for vapers not to go back to smoking. Without paying attention to this fact, the Dutch State Secretary Paul Blokhuis has announced to ban all e-cigarette flavours except ...
moreCOVID-19: Use rapid tests to identify important biomarkers and predict the course of the disease
Moers (ots) - Whether it’s a lung embolism or a heart attack – an infection with coronavirus can have life-threatening consequences. But how badly will different patients be affected by COVID-19? This can be determined by certain biomarkers. nal von minden GmbH’s biomarker rapid tests from Germany deliver reliable results in just 15 minutes. An infection with ...
moreTechnische Universität München
Breathing rate predicts therapeutic benefits for heart patients
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36385/ NEWS RELEASE Discovering a forgotten biosignal Breathing rate predicts therapeutic benefits for heart patients Conditions causing arrhythmia are among ...
moreTechnische Universität München
Sixfold increase in risk: study shows link between cervical cancer and HIV infection
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36390/ High resolution images: https://mediatum.ub.tum.de/1585216 NEWS RELEASE Sixfold increase in risk Link between cervical cancer and HIV infection A ...
moreEANS-News: AGRANA: Weekly rapid coronavirus tests for employees prove their worth
issuer: AGRANA Beteiligungs-AG F.-W.-Raiffeisen-Platz 1 A-1020 Wien phone: +43-1-21137-0 FAX: +43-1-21137-12926 mail: info.ab@agrana.com WWW: www.agrana.com ISIN: AT000AGRANA3 indexes: WBI stockmarkets: Frankfurt, Berlin, Stuttgart, Wien language: ...
more
nal von minden plans to produce 80 million rapid corona tests per month
moreNew: Combined rapid test for Covid-19 and influenza
moreUMIT - The Health & Life Sciences University
University UMIT TIROL publishes the first population model to evaluate benefits and harms of universal salt iodization
Hall in Tirol (ots) - An article recently published by Schaffner and colleagues in the medical journal "Thyroid" summarizes the results of a decision-analytic population modeling study evaluating the benefits and harms of universal salt iodization. Iodine is a micronutrient that is essential for the production of ...
moreSysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating RAS mutation status in circulating tumor DNA (ctDNA) of colorectal cancer (CRC) patients undergoing anti-EGFR ...
moreSysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing
Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care ...
moreVersameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials
Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...
more
Previous12345678Next